PubAg

Main content area

Age-dependent differences in response to partial-thickness cartilage defects in a rat model as a measure to evaluate the efficacy of interventions for cartilage repair

Author:
Akatsu, Yorikazu, Enomoto, Takahiro, Yamaguchi, Satoshi, Tahara, Masamichi, Fukawa, Taisuke, Endo, Jun, Hoshi, Hiroko, Yamamoto, Yohei, Sasaki, Toshihide, Takahashi, Kazuhisa, Akagi, Ryuichiro, Sasho, Takahisa
Source:
Cell and tissue research 2019 v.375 no.2 pp. 425-435
ISSN:
0302-766X
Subject:
animal models, cartilage, drugs, immunohistochemistry, mesenchymal stromal cells, osteoarthritis, rats
Abstract:
The objectives of this study are (1) to examine age-dependent longitudinal differences in histological responses after creation of partial-thickness articular cartilage defects (PTCDs) in rats and to use this model (2) to objectively evaluate the effectiveness of interventions for cartilage repair. Linear PTCDs were created at a depth of 100 μm in the weight-bearing region of the medial femoral condyle in rats of different ages (3 weeks, 6 weeks, 10 weeks and 14 weeks). One day, one week, two weeks, four weeks and twelve weeks after PTCD generation, spontaneous healing was evaluated histologically and immunohistochemically. Effects of interventions comprising mesenchymal stem cells (MSCs) or platelet-rich plasma (PRP) or both on 14-week-old PTCD rats were evaluated and compared with natural courses in rats of other ages. Younger rats exhibited better cartilage repair. Cartilage in 3-week-old and 6-week-old rats exhibited nearly normal restoration after 4–12 weeks. Cartilage in 14-week-old rats deteriorated over time and early signs of cartilage degeneration were observed. With injection of MCSs alone or MSCs + PRP, 14-week-old PTCD rats showed almost the same reparative cartilage as 6-week-old rats. With injection of PRP, 14-week-old PTCD rats showed almost the same reparative cartilage as 10-week-old rats. This model will be of great use to objectively compare the effects of interventions for small cartilage lesions and may help to advance the development of disease-modifying osteoarthritis drugs.
Agid:
6303325